VOCLAV 625

Diagnostics Innovation Biotech Environment Testing Research Diagnostics Innovation Biotech
Diagnostics Innovation Biotech Environment Testing Research Diagnostics Innovation Biotech
Pantalis 40 Injection VOCLAV 625 Rbvoc-DSR Rabeprazole Listuss - Syrup Vocalis SP Pantalis-D Listus-AM DIVOC CEFOTEM-1.5 INJ CEFTRALIS INJ
VOCLAV 625 Rbvoc-DSR Rabeprazole Listuss - Syrup Vocalis SP Pantalis-D Listus-AM DIVOC VOCLAV 625 Azivoc-500 tab Rbvoc-DSR Rabeprazole

Explore Our Prodcuts

VOCLAV 625 provides broad-spectrum, effective treatment for a wide range of bacterial infections. Formulated with a synergistic combination of Amoxicillin (500 mg) and Clavulanic Acid (125 mg), it works by inhibiting bacterial cell wall synthesis and preventing resistance through β-lactamase inhibition. This dual mechanism ensures reliable eradication of infection-causing pathogens, even those resistant to conventional antibiotics.

It is highly effective in the management of respiratory tract infections, urinary tract infections, skin & soft tissue infections, bone & joint infections, and ENT infections. With proven efficacy and safety, VOCLAV 625 is trusted as a first-line therapy in both hospital and outpatient settings.

Backed by clinical data, VOCLAV 625 demonstrates a high success rate in bacterial clearance, reduced recurrence, and faster symptom relief, making it a safe and dependable antimicrobial solution.

Research & Clinical Data for VOCLAV 625

Indications Supported by Evidence

  • Respiratory Tract Infections (Bronchitis, Pneumonia, Sinusitis, Tonsillitis): Demonstrated rapid symptom resolution and high bacterial clearance.
  • Urinary Tract Infections: Proven efficacy against resistant gram-negative and gram-positive bacteria.
  • Skin, Soft Tissue, Bone & Joint Infections: Shown to accelerate healing, reduce inflammation, and prevent recurrence.
  • ENT Infections: Effective in otitis media, sinusitis, and pharyngitis with significant clinical improvement.